High rates of durable responses with anti-CD22 fractionated radioimmunotherapy: Results of a multicenter, phase I/II study in non-Hodgkin's lymphoma

Journal of Clinical Oncology

Volumn 28, Issue 23, 2010, Pages 3709-3716

  Morschhauser, Franck ^a   Kraeber Bodéré, Françoise ^a   Wegener, William A ^a   Harousseau, Jean Luc ^a   Petillon, Marie Odile ^a   Huglo, Damien ^a   Trümper, Lorenz H ^a   Meller, Johannes ^a   Pfreundschuh, Michael ^a   Kirsch, Carl Martin ^a   Naumann, Ralph ^a   Kropp, Joachim ^a   Horne, Heather ^a   Teoh, Nick ^a   Le Gouill, Steven ^a   Bodet Milin, Caroline ^a   Chatal, Jean Francois ^a   Goldenberg, David M ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

CD22 ANTIGEN; EPRATUZUMAB; EPRATUZUMAB TETRAXETAN Y 90; INDIUM 111; UNCLASSIFIED DRUG; YTTRIUM 90; ANTINEOPLASTIC AGENT; HLL2 AGENT; MONOCLONAL ANTIBODY; YTTRIUM;

ADULT; AGED; ANEMIA; ARTICLE; ASTHENIA; AUTOLOGOUS STEM CELL TRANSPLANTATION; BACKACHE; CONSTIPATION; COUGHING; DRUG EFFICACY; DRUG FEVER; DRUG SAFETY; FEMALE; FOLLICULAR LYMPHOMA; HEADACHE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MYALGIA; NAUSEA; NEUTROPENIA; NONHODGKIN LYMPHOMA; PAIN; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RADIOIMMUNOTHERAPY; THROMBOCYTOPENIA; TREATMENT RESPONSE; VOMITING; CLINICAL TRIAL; MIDDLE AGED; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; FEMALE; HUMANS; LYMPHOMA, NON-HODGKIN; MALE; MIDDLE AGED; RADIOIMMUNOTHERAPY; TREATMENT OUTCOME; YOUNG ADULT; YTTRIUM RADIOISOTOPES;

EID: 77957272703     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2009.27.7863     Document Type: Article

References (43)

1. Goldenberg DM, DeLand F, Kim E, et al: Use of radiolabeled antibodies to carcinoembryonic antigen for the detection and localization of diverse cancers by external photoscanning. N Engl J Med 298:1384-1386, 1978
2. Sharkey RM, Goldenberg DM: Targeted therapy of cancer: New prospects for antibodies and immunoconjugates. CA Cancer J Clin 56:226-243, 2006 (Pubitemid 44175051)
3. Cheson BD, Leonard JP: Monoclonal antibody therapy for B-cell non-Hodgkin's lymphoma. N Engl J Med 359:613-626, 2008
4. McLaughlin P, Grillo-Lopez AJ, Link BK, et al: Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: Half of patients respond to a four-dose treatment program. J Clin Oncol 16:2825-2833, 1998 (Pubitemid 28363048)
5. Piro LD, White CA, Grillo-López AJ, et al: Extended rituximab (anti-CD20 monoclonal antibody) therapy for relapsed or refractory low-grade or follicular non-Hodgkin's lymphoma. Ann Oncol 10: 655-661, 1999 (Pubitemid 29342370)
6. Marcus R, Imrie K, Belch A, et al: CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma. Blood 105:1417-1423, 2005 (Pubitemid 40223656)
7. Hiddemann W, Kneba M, Dreyling M, et al: Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: Results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood 106:3725-3732, 2005 (Pubitemid 41742196)
8. Herold M, Haas A, Srock S, et al: Rituximab added to first-line mitoxantrone, chlorambucil, and prednisolone chemotherapy followed by interferon maintenance prolongs survival in patients with advanced follicular lymphoma: An East German Study Group Hematology and Oncology Study. J Clin Oncol 25:1986-1992, 2007
9. Witzig TE, White CA, Wiseman GA, et al: Phase I/II trial of IDEC-Y2B8 radioimmunotherapy for treatment of relapsed or refractory CD20+ B-cell non- Hodgkin's lymphoma. J Clin Oncol 17:3793-3803, 1999
10. Witzig TE, Gordon LI, Cabanillas F, et al: Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. J Clin Oncol 20: 2453-2463, 2002 (Pubitemid 34525730)
11. Kaminski MS, Estes J, Zasadny KR, et al: Radioimmunotherapy with iodine (131)I tositumomab for relapsed or refractory B-cell non-Hodgkin lymphoma: Updated results and long-term follow-up of the University of Michigan experience. Blood 96:1259-1266, 2000
12. Vose JM, Wahl RL, Saleh M, et al: Multicenter phase II study of iodine-131 tositumomab for chemotherapy- relapsed/refractory low-grade and transformed low-grade B-cell non-Hodgkin's lymphomas. J Clin Oncol 18:1316-1323, 2000 (Pubitemid 30159851)
13. Kaminski MS, Zelenetz AD, Press OW, et al: Pivotal study of iodine I 131 tositumomab for chemotherapy- refractory low-grade or transformed lowgrade B-cell non-Hodgkin's lymphomas. J Clin Oncol 19:3918-3928, 2001 (Pubitemid 32912019)
14. Davies AJ, Rohatiner AZ, Howell S, et al: Tositumomab and iodine I 131 tositumomab for recurrent indolent and transformed B-cell non-Hodgkin's lymphoma. J Clin Oncol 22:1469-1479, 2004 (Pubitemid 41103630)
15. Morschhauser F, Radford J, Van Hoof A, et al: Phase III trial of consolidation therapy with yttrium- 90-ibritumomab tiuxetan compared with no additional therapy after first remission in advanced follicular lymphoma. J Clin Oncol 26:5156-5164, 2008
16. Press OW, Unger JM, Braziel RM, et al: Phase II trial of CHOP chemotherapy followed by tositumomab/iodine I-131 tositumomab for previously untreated follicular non-Hodgkin's lymphoma: Five-year follow-up of Southwest Oncology Group Protocol S9911. J Clin Oncol 24:4143-4149, 2006 (Pubitemid 46622291)
17. Kaminski MS, Tuck M, Estes J, et al: 131 I-tositumomab therapy as initial treatment for follicular lymphoma. N Engl J Med 352:441-449, 2005 (Pubitemid 40175970)
18. Witzig TE, Molina A, Gordon LI, et al: Longterm responses in patients with recurring or refractory B-cell non-Hodgkin lymphoma treated with yttrium 90 ibritumomab tiuxetan. Cancer 109:1804- 1810, 2007
19. Press OW: Evidence mounts for the efficacy of radioimmunotherapy for B-cell lymphomas. J Clin Oncol 26:5147-5150, 2008
20. Cesano A, Gayko, U, Brannan C, et al: Differential expression of CD22 in indolent and aggressive non-Hodgkin's lymphoma (NHL): Implications for targeted therapy. Blood 100: 350a, 2002 (suppl; abstr 1358)
21. Goldenberg DM: Epratuzumab in the therapy of oncological and immunological diseases. Expert Rev Anticancer Ther 6:1341-1353, 2006
22. Leonard JP, Coleman M, Ketas JC, et al: Phase I/II trial of epratuzumab (humanized anti-CD22 antibody) in indolent non-Hodgkin's lymphoma. J Clin Oncol 21:3051-3059, 2003 (Pubitemid 46606284)
23. Leonard JP, Coleman M, Ketas JC, et al: Epratuzumab, a humanized anti-CD22 antibody, in aggressive non-Hodgkin's lymphoma: Phase I/II clinical trial results. Clin Cancer Res 10:5327-5334, 2004 (Pubitemid 39100467)
24. Shih LB, Lu HH, Xuan H, Goldenberg DM: Internalization and intracellular processing of an anti- B-cell lymphoma monoclonal antibody, LL2. Int J Cancer 56:538-545, 1994 (Pubitemid 24094405)
25. Carnahan J, Stein R, Qu Z, et al: Epratuzumab, a CD22-targeting recombinant humanized antibody with a different mode of action from rituximab. Mol Immunol 44:1331-1341, 2007 (Pubitemid 44415959)
26. Sharkey RM, Behr TM, Mattes MJ, et al: Advantage of residualizing radiolabels for an internalizing antibody against the B-cell lymphoma antigen, CD22. Cancer Immunol Immunother 44:179-188, 1997 (Pubitemid 27278391)
27. Griffiths GL, Govindan SV, Sharkey RM, et al: 90Y-DOTA-hLL2: An agent for radioimmunotherapy of non-Hodgkin's lymphoma. J Nucl Med 44:77-84, 2003 (Pubitemid 36077716)
28. 90Y-epratuzumab): Do tumor targeting and dosimetry predict therapeutic response? J Nucl Med 44:2000- 2018, 2003
29. DeNardo GL, Schlom J, Buchsbaum DJ, et al: Rationales, evidence, and design considerations for fractionated radioimmunotherapy. Cancer 94:1332-1348, 2002 (Pubitemid 34150897)
30. 90Y-radiolabeled, humanized anti-CD22 monoclonal antibody, epratuzumab. Clin Cancer Res 11:5215-5222, 2005
31. Harris NL, Ferry JA: Classification of non- Hodgkin's lymphoma, in Knowles DM (ed): Neoplastic Hematopathology (ed 2). Philadelphia, PA, Lippincott Williams & Wilkins, 2001, pp 691-753
32. Solal-Céligny P, Roy P, Colombat P, et al: Follicular lymphoma international prognostic index. Blood 104:1258-1265, 2004 (Pubitemid 39166497)
33. Cheson BD, Horning S, Coiffier B, et al: Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. J Clin Oncol 17:1244-1253, 1999 (Pubitemid 29162950)
34. 18F-fluorodeoxyglucose positron emission tomography. Haematologica 93:390-397, 2008
35. Tam CS, Wolf M, Prince HM, et al: Fludarabine, cyclophosphamide, and rituximab for the treatment of patients with chronic lymphocytic leukemia or indolent non-Hodgkin lymphoma. Cancer 106: 2412-2420, 2006 (Pubitemid 43791961)
36. Forstpointner R, Dreyling M, Repp R, et al: The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle cell lymphomas: Results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood 104:3064-3071, 2004 (Pubitemid 39517009)
37. Witzig TE, Flinn IW, Gordon LI, et al: Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non- Hodgkin's lymphoma. J Clin Oncol 20:3262-3269, 2002 (Pubitemid 34831524)
38. 90yttrium Ibritumomab tiuxetan (Zevalin) with PBSC support in refractory-resistant NHL patients. Blood 110:560a, 2007 (suppl; abstr 1890)
39. Devizzi L, Guidetti A, Tarella C, et al: Highdose yttrium-90-ibritumomab tiuxetan with tandem stem-cell reinfusion: An outpatient preparative regimen for autologous hematopoietic cell transplantation. J Clin Oncol 26:5175-5182, 2008
40. Illidge TM, Bayne M, Brown NS, et al: Phase 1/2 study of fractionated (131)I-rituximab in lowgrade B-cell lymphoma: The effect of prior rituximab dosing and tumor burden on subsequent radioimmunotherapy. Blood 113:1412-1421, 2009
41. Gopal AK, Press OW, Wilbur SM, et al: Rituximab blocks binding of radiolabeled anti-CD20 antibodies (Ab) but not radiolabeled anti-CD45 Ab. Blood 112:830-835, 2008
42. Sharkey RM, Press OW, Goldenberg DM: A re-examination of radioimmunotherapy in the treatment of non-Hodgkin lymphoma: Prospects for dual-targeted antibody/radioantibody therapy. Blood 113: 3891-3895, 2009
43. 90Y-anti-CD22 IgG (epratuzumab) and unlabeled anti-CD20 IgG (veltuzumab). Clin Cancer Res 14:6154-6160, 2008